The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
News|Articles|March 2, 2014
Capsule filler
Capsule filler
Advertisement
MG America offers the new FlexaLAB Capsule Filler, which can produce up to 3000 capsules/hr. Specifically designed for R&D labs, clinical trials, small batch outputs and special productions, Flexa-LAB can function at continuous or intermittent motion. Multiple dosing units can be utilized simultaneously, enabling the FlexaLAB to manufacture capsules with product combinations.
MG America, Fairfield, NJ
•
INTERPHEX Booth # 2253
Advertisement
Related to this article
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
2
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
3
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
4
Ask the Expert: Post-Approval Changes
5